Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,781 INR | +1.19% |
|
+4.01% | +7.88% |
05-14 | Nomura Upgrades Dr. Lal Pathlabs to Buy From Neutral, Adjusts Price Target to INR2,713 From INR2,505 | MT |
05-13 | Dr. Lal Pathlabs' Fiscal Q4 Consolidated Net Profit Rises; Share Up 6% | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 55.3 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.88% | 2.78B | B- | ||
-18.02% | 8.43B | B+ | ||
+69.46% | 4.35B | C+ | ||
-1.93% | 2.64B | - | ||
-14.28% | 1.77B | C- | ||
-56.54% | 1.74B | B- | ||
-16.69% | 1.48B | A- | ||
+17.87% | 1.22B | B+ | ||
-49.60% | 1.02B | C+ | ||
+10.83% | 922M | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LALPATHLAB Stock
- Ratings Dr. Lal PathLabs Limited